Lagarde C, Hamel-Teillac D, De Prost Y, Blanche S, Thomas C, Fischer A, Nordmann Y, Ged C, De Verneuil H
Service de Dermatologie, Hôpital Necker-Enfants Malades, Paris.
Ann Dermatol Venereol. 1998 Feb;125(2):114-7.
The congenital erythropoietic porphyria (Günther's disease) (CEP) is a rare autosomal recessively metabolic disease due to the deficit of uroporphyrinogen III cosynthetase, fourth enzyme of the porphyrin-heme biosynthesis. This disease is characterized by severe cutaneous photosensitivity with profound skin lesions, hemolytic anemia and excess of uroporphyrin I excretion. The vital prognosis is very bad and until now, no treatment seems to be efficient. Bone marrow transplantation seems to be able to correct the enzymatic deficit that causes the disease because it is located in the bone marrow.
We report the case of a four and a half year old girl who received an allogeneic bone marrow transplantation (BMT) at the age of two. Despite an encouraging result, the first transplantation failed. A second allogeneic transplantation was attempted eight months later with the same HLA identical heterozygous donor and bone marrow engrafment succeeded. Twenty one months after the second bone marrow transplantation, clinical and biological results are still excellent.
No classical treatment of CEP really proved its efficiency and no one was curative. CEP resulting from an homozygous deficiency in uroporphyrinogen III cosynthetase, enzyme that takes part in the porphyrin-heme biosynthesis which is principally located in the erythropoietic system of the bone marrow, substitution of this defective lineage by BMT was a very attractive treatment to correct this anomaly. The first bone marrow transplantation attempted on an affected child in 1990 in Manchester failed because the patient died of infections complications. After the failure of the first transplantation, our little patient is now healed twenty one months after the second BMT and biochemical anomalies are corrected. If a long follow up is necessary to appreciate the long-term efficiency of this treatment, allogenic bone marrow transplantation seems to cure Günther's disease and must be proposed as the treatment of this affection.
先天性红细胞生成性卟啉病(贡瑟病)(CEP)是一种罕见的常染色体隐性代谢疾病,因尿卟啉原III同合成酶(卟啉 - 血红素生物合成的第四种酶)缺乏所致。该疾病的特征为严重的皮肤光敏感性,伴有严重的皮肤病变、溶血性贫血以及尿卟啉I排泄过量。其生命预后非常差,迄今为止,尚无有效的治疗方法。骨髓移植似乎能够纠正导致该疾病的酶缺陷,因为这种缺陷存在于骨髓中。
我们报告一例4岁半女孩的病例,她在2岁时接受了异基因骨髓移植(BMT)。尽管结果令人鼓舞,但首次移植失败。8个月后,使用相同的HLA配型相合的杂合供体进行了第二次异基因移植,骨髓植入成功。第二次骨髓移植21个月后,临床和生物学结果仍然非常好。
CEP的传统治疗方法均未真正证明其有效性,也无一具有治愈性。CEP是由于尿卟啉原III同合成酶纯合缺陷所致,该酶参与卟啉 - 血红素生物合成,主要位于骨髓的红细胞生成系统中,通过BMT替代这种有缺陷的谱系是纠正这一异常的极具吸引力的治疗方法。1990年在曼彻斯特对一名患病儿童进行的首次骨髓移植失败,因为患者死于感染并发症。首次移植失败后,我们的小患者在第二次BMT后21个月现已康复,生化异常得到纠正。如果需要长期随访以评估这种治疗方法的长期疗效,异基因骨髓移植似乎可以治愈贡瑟病,必须将其作为这种疾病的治疗方法。